Background: The Extrapyramidal Symptom Rating Scale – Abbreviated (ESRS-A) is an abbreviated version of the Extrapyramidal Symptom Rating Scale (ESRS) with instructions, definitions, and a semi-structured interview that follows clinimetric concepts of measuring clinical symptoms. Similar to the ESRS, the ESRS-A was developed to assess four types of drug-induced movement disorders (DIMD): parkinsonism, akathisia, dystonia, and tardive dyskinesia (TD). Summary: The present review of the literature provides the most relevant clinimetric properties displayed by the ESRS and ESRS-A in clinical studies. Comprehensive ESRS-A definitions, official scale, and basic instructions are provided. ESRS inter-rater reliability was evaluated in two pivotal studies and in multicenter international studies. Inter-rater reliability was high for assessing both antipsychotic-induced movement disorders and idiopathic Parkinson’s disease. Guidelines were also established for inter-rater reliability and the rater certification processes. The ESRS showed good concurrent validity with 96% agreement between Abnormal Involuntary Movement Scale (AIMS) for TD-defined cases and ESRS-defined cases. Similarly, concurrent validity for ESRS-A total and subscores for parkinsonism, akathisia, dystonia, and dyskinesia ranged from good to very good. The ESRS was particularly sensitive for detecting DIMD-related movement differences following treatment with placebo, antipsychotics, and antiparkinsonian and antidyskinetic medications. ESRS measurement of drug-induced extrapyramidal symptoms was shown to discriminate extrapyramidal symptoms from psychiatric symptoms. Key Messages: The ESRS and ESRS-A are valid clinimetric indices for measuring DIMD. They can be valuably implemented in clinical research, particularly in trials testing antipsychotic medications, and in clinics to detect the presence, severity, and response to treatment of movement disorders.

1.
Chouinard
G
.
New nomenclature for drug-induced movement disorders including tardive dyskinesia
.
J Clin Psychiatry
.
2004
65
Suppl 9
9
15
.
2.
Margolese
HC
,
Chouinard
G
,
Walters-Larach
V
,
Beauclair
L
.
Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine
.
Acta Psychiatrica Belgica
.
2001
;
101
:
128
44
.
3.
Feinstein
AR
Clinimetrics
Yale
Yale University Press
1982
.
4.
Fava
GA
,
Carrozzino
D
,
Lindberg
L
,
Tomba
E
.
The clinimetric approach to psychological assessment: a tribute to per bech, MD (1942–2018)
.
Psychother Psychosom
.
2018
;
87
(
6
):
321
6
.
5.
Fava
GA
.
Forty years of clinimetrics
.
Psychother Psychosom
.
2022
;
91
:
1
7
.
6.
Cosci
F
.
Clinimetric perspectives in clinical psychology and psychiatry
.
Psychother Psychosom
.
2021
;
90
(
4
):
217
21
.
7.
Carrozzino
D
,
Patierno
C
,
Guidi
J
,
Berrocal Montiel
C
,
Cao
J
,
Charlson
ME
.
Clinimetric criteria for patient-reported outcome measures
.
Psychother Psychosom
.
2021
;
90
(
4
):
222
32
.
8.
Charlson
ME
,
Carrozzino
D
,
Guidi
J
,
Patierno
C
.
Charlson Comorbidity Index: a critical review of clinimetric properties
.
Psychother Psychosom
.
2022
;
91
(
1
):
8
35
.
9.
Hanlon
JT
,
Schmader
KE
.
The medication appropriateness index: a clinimetric measure
.
Psychother Psychosom
.
2022
;
91
(
2
):
78
83
.
10.
Chouinard
G
,
Margolese
HC
.
Manual for the extrapyramidal symptom rating scale (ESRS)
.
Schizophr Res
.
2005
76
2–3
247
65
.
11.
Chouinard
G
,
Annable
L
,
Ross-Chouinard
A
,
Nestoros
JN
.
Factors related to tardive dyskinesia
.
Am J Psychiatry
.
1979
;
136
(
1
):
79
82
.
12.
Chouinard
G
,
Annable
L
,
Ross-Chouinard
A
,
Mercier
P
.
A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases
.
J Clin Psychopharmacol
.
1988
8
4 Suppl
21S
6S
.
13.
Chouinard
G
,
Annable
L
.
Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit
.
Am J Psychiatry
.
1976
;
133
(
7
):
850
3
.
14.
Chouinard
G
,
Annable
L
.
Pimozide in the treatment of newly admitted schizophrenic patients
.
Psychopharmacology
.
1982
;
76
(
1
):
13
9
.
15.
Chouinard
G
,
Annable
L
,
Ross-Chouinard
A
.
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect
.
Am J Psychiatry
.
1982
;
139
(
3
):
312
8
.
16.
Chouinard
G
,
Annable
L
,
Campbell
W
.
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia
.
J Clin Psychopharmacol
.
1989
;
9
(
4
):
247
53
.
17.
Chouinard
G
,
Annable
L
,
Ross-Chouinard
A
,
Kropsky
ML
.
Ethopropazine and benztropine in neuroleptic-induced parkinsonism
.
J Clin Psychiatry
.
1979
;
40
(
3
):
147
52
.
18.
Chouinard
G
,
de Montigny
C
,
Annable
L
.
Tardive dyskinesia and antiparkinsonian medication
.
Am J Psychiatry
.
1979
;
136
(
2
):
228
9
.
19.
Chouinard
G
,
Annable
L
,
Mercier
P
,
Turnier
L
.
Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms
.
Psychopharmacol Bull
.
1987
;
23
(
1
):
221
6
.
20.
de Montigny
C
,
Chouinard
G
,
Annable
L
.
Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study
.
Psychopharmacology
.
1979
;
65
(
3
):
219
23
.
21.
Chouinard
G
,
Young
SN
,
Annable
L
.
Antimanic effect of clonazepam
.
Biol Psychiatry
.
1983
;
18
(
4
):
451
66
.
22.
Chouinard
G
,
Young
SN
,
Annable
L
.
A controlled clinical trial of L-tryptophan in acute mania
.
Biol Psychiatry
.
1985
;
20
(
5
):
546
57
.
23.
Chouinard
G
,
Annable
L
,
Serrano
M
,
Charette
R
.
A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients
.
Int Pharmacopsychiatry
.
1977
;
12
:
1
8
.
24.
Chouinard
G
,
Annable
L
,
Young
SN
,
Sourkes
TL
.
Tryptophan-benserazide in the treatment of schizophrenia
.
Commun Psychopharmacol
.
1978
;
2
:
21
31
.
25.
Chouinard
G
.
A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation
.
Acta Psychiatr Scand Suppl
.
1990
;
358
:
111
9
.
26.
Chouinard
G
,
Jones
B
,
Remington
G
,
Bloom
D
,
Addington
D
,
MacEwan
GW
.
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
.
J Clin Psychopharmacol
.
1993
;
13
(
1
):
25
40
.
27.
Chouinard
G
.
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study
.
J Clin Psychopharmacol
.
1995
15
1 Suppl 1
36S
44S
.
28.
Jeste
DV
,
Okamoto
A
,
Napolitano
J
,
Kane
JM
,
Martinez
RA
.
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone
.
Am J Psychiatry
.
2000
;
157
(
7
):
1150
5
.
29.
Meltzer
HY
,
Alphs
L
,
Green
AI
,
Altamura
AC
,
Anand
R
,
Bertoldi
A
.
Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT)
.
Arch Gen Psychiatry
.
2003
;
60
(
1
):
82
91
.
30.
Chouinard
G
,
Margolese
HC
,
Alphs
L
,
Larach-Walters
V
,
Beauclair
L
,
Anand
R
.
Relationship between baseline extrapyramidal symptoms and suicidality in schizophrenic subjects included in the InterSePT trial
.
Biol Psychiatry
.
2002
51
20S
1S
.
31.
Chouinard
G
,
Bhanji
NH
,
Light
M
,
Margolese
HC
.
Patient characteristics, symptom severity, and movement disorders in patients with schizophrenia and schizoaffective disorder
.
Biol Psychiatry
.
2003
53
21S
.
32.
Marder
SR
,
Davis
JM
,
Chouinard
G
.
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
.
J Clin Psychiatry
.
1997
;
58
(
12
):
538
46
.
33.
Möller
HJ
,
Müller
H
,
Borison
RL
,
Schooler
NR
,
Chouinard
G
.
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
.
Eur Arch Psychiatry Clin Neurosci
.
1995
;
245
(
1
):
45
9
.
34.
Chouinard
G
,
Ross-Chouinard
A
,
Annable
L
,
Jones
B
.
The extrapyramidal symptom rating scale
.
Can J Neurol Sci
.
1980
;
7
(
3
):
233
.
35.
Chouinard
G
,
Ross-Chouinard
A
,
Gauthier
S
,
Annable
L
,
Mercier
P
.
An extrapyramidal rating scale for idiopathic and neuroleptic-induced parkinsonism and dyskinesia
.
Collegium Internationale Neuro-Psychopharmacologicum (C. I. N. P.) 14th congress, Book of Abstracts
.
1984
. p.
16
.
36.
Marder
SR
,
Meibach
RC
.
Risperidone in the treatment of schizophrenia
.
Am J Psychiatry
.
1994
;
151
(
6
):
825
35
.
37.
Gharabawi
GM
,
Bossie
CA
,
Lasser
RA
,
Turkoz
I
,
Rodriguez
S
,
Chouinard
G
.
Abnormal involuntary movement scale (AIMS) and extrapyramidal symptom rating scale (ESRS): cross-scale comparison in assessing tardive dyskinesia
.
Schizophr Res
.
2005
77
2–3
119
28
.
38.
Alphs
L
,
Bossie
CA
,
Turkoz
I
ISCTM 6th annual scientific meeting 22–24 February 2010
Washington, D.C
.
39.
Dion
Y
,
Annable
L
,
Sandor
P
,
Chouinard
G
.
Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial
.
J Clin Psychopharmacol
.
2002
;
22
(
1
):
31
9
.
40.
Purdon
SE
,
Jones
BD
,
Stip
E
,
Labelle
A
,
Addington
D
,
David
SR
.
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia
.
Arch Gen Psychiatry
.
2000
;
57
(
3
):
249
58
.
41.
Simpson
GM
,
Angus
JW
.
A rating scale for extrapyramidal side effects
.
Acta Psychiatr Scand Suppl
.
1970
;
212
:
11
9
.
42.
Fahn
S
,
Elton
RL
.
Unified Parkinson’s disease rating scale
. In:
Fahn
S
,
Marsden
CD
,
Goldstein
M
,
Calne
DB
, editors.
Recent developments in Parkinson’s disease
Florham Park NJ
Macmillan Healthcare Information
1987
. p.
153
63
.
43.
Hoehn
MM
,
Yahr
MD
.
Parkinsonism: onset, progression and mortality
.
Neurology
.
1967
;
17
(
5
):
427
42
.
44.
Hoehn
MM
,
Yahr
MD
.
Parkinsonism: onset, progression, and mortality
.
Neurology
.
2001
57
10 Suppl 3
S11
26
.
45.
Guy
E
Abnormal involuntary movement scale. ECDEU assessment manuel for psychopharmacology: revised 1976
Rockville (MD)
National Institute of Mental Health, U.S. Department of Health and Human Services
1976
.
46.
Munetz
MR
,
Benjamin
S
.
How to examine patients using the abnormal involuntary movement scale
.
Hosp Community Psychiatry
.
1988
;
39
(
11
):
1172
7
.
47.
Correll
CU
,
Leucht
S
,
Kane
JM
.
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
.
Am J Psychiatry
.
2004
;
161
:
414
25
.
48.
Schooler
NR
,
Kane
JM
.
Research diagnoses for tardive dyskinesia
.
Arch Gen Psychiatry
.
1982
;
39
(
4
):
486
7
.
49.
American Psychiatric Association
Diagnostic and statistical manual of mental disorders. 4th, text rev. (DSM-IV-TR)
Washington, DC
American Psychiatric Press
2000
.
50.
Chouinard
G
,
Bhanji
NH
,
Light
M
,
Margolese
HC
.
Patient characteristics, symptom severity, and movement disorders in patients with schizophrenia and schizoaffective disorder
.
Biol Psychiatry
.
2003
53
S21
.
51.
Kane
JM
,
Eerdekens
M
,
Lindenmayer
JP
,
Keith
SJ
,
Lesem
M
,
Karcher
K
.
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
.
Am J Psychiatry
.
2003
;
160
(
6
):
1125
32
.
52.
Chouinard
G
,
Chouinard
VA
.
Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes
.
Psychother Psychosom
.
2008
;
77
(
2
):
69
77
.
53.
Fleischhacker
WW
,
Eerdekens
M
,
Karcher
K
,
Remington
G
,
Llorca
PM
,
Chrzanowski
W
.
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic
.
J Clin Psychiatry
.
2003
;
64
(
10
):
1250
7
.
54.
Chue
P
,
Eerdekens
M
,
Augustyns
I
,
Lachaux
B
,
Molcan
P
,
Eriksson
L
.
Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets
. American College of Neuropsychopharmacology Annual Meeting. December 9–13, 2001, Waikoloa, HI, USA.
55.
International Early Psychosis Association Writing Group
.
International clinical practice guidelines for early psychosis
.
Br J Psychiatry Suppl
.
2005
48
s120
4
.
56.
Chouinard
G
,
Samaha
AN
,
Chouinard
VA
,
Peretti
CS
,
Kanahara
N
,
Takase
M
.
Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria and therapy
.
Psychother Psychosom
.
2017
;
86
(
4
):
189
219
.
You do not currently have access to this content.